Pasithea shares jump 13.28% after-hours as Nasdaq confirms compliance with minimum bid price requirement.

Pasithea Therapeutics surged 13.28% in after-hours trading after announcing it regained Nasdaq compliance with the minimum $1.00 bid price requirement, resolving a 180-day deadline that ended on December 22, 2025. Nasdaq confirmed the matter is now closed, alleviating concerns about potential delisting and boosting investor confidence in the company’s continued market presence. The news followed earlier reports of the stock trading above $1.00 for sufficient consecutive days, with shares currently at $1.13. While the company also disclosed progress on its drug candidate PAS-004 and an ALS-related grant, the immediate catalyst for the after-hours rally was the compliance resolution, which directly addresses a critical regulatory hurdle.